PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy
Advanced Science · 2026-11 · 13 (61)
DOI: 10.1002/advs.77089 ↗At a glance
Journal article in Advanced Science, published online on 2026-08-11. Written by Peng Liu and 4 co-authors. Institution: Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, China. Major MEDLINE topics: Dendritic Cells, Cancer Vaccines, Immunotherapy, Neoplasms. 33 references. The full text is freely available (open access, CC BY 4.0). Funded by: Tianshan Talent Training Program, Major science and technology program in Xinjiang Uygur Autonomous Region, National Natural Science Foundation of China.
Abstract (original language)
The efficacy of dendritic cell (DC) vaccines in cancer immunotherapy is often limited by weak immunogenicity due to inefficient antigen cross‐presentation (XPT). We previously combined a calcium carbonate (CaCO 3 ) delivery system with a proteolysis‐targeting chimera (PROTAC) to enhance antigen degradation. Along this line, we developed a protein/DNA‐integrated nanoantigen platform (HpOAC) co‐loading CaCO 3 with a His‐tagged ovalbumin (O) modified with the von Hippel‐Lindau (VHL) E3 ligase‐recruiting peptide ALAPYIP (HOA) and a eukaryotic plasmid encoding O‐ALAPYIP (pOA). HpOAC promoted DC maturation and migration via Ca 2+ release. Mechanistically, HOA provided an immediate antigen source, while pOA enabled sustained expression; both underwent ALAPYIP‐mediated VHL recruitment, enhancing O ubiquitination and proteasomal degradation, thereby amplifying XPT. Consequently, HpOAC‐DCs induced strong OT‐I/OT‐II T cell proliferation in vitro. In vivo, a single immunization with HpOAC‐DCs significantly suppressed tumor growth and elicited durable antigen‐specific T helper type 1 and cytotoxic T lymphocyte responses, outperforming single‐antigen vaccines. Under a two‐dose regimen, its anti‐tumor efficacy was improved compared to non‐PROTAC and in situ antigen vaccines. Thus, we constructed a PROTAC‐enhanced, protein/DNA‐integrated DC vaccine platform that synergizes immediate and sustained antigen supply with Ca 2+ ‐mediated adjuvanticity, offering a highly promising strategy for novel DC vaccine design.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, China.
ORCID profiles: Peng Liu, Qiang Chen, Yuekang Xu, Jinyao Li
Funding
- Tianshan Talent Training Program
- Major science and technology program in Xinjiang Uygur Autonomous Region
- National Natural Science Foundation of China
- Graduate Research Innovation Project of Xinjiang Uygur Autonomous Region
- Outstanding Doctoral Innovation Project of Xinjiang University
Cite
APA
Liu, P., Chen, Q., Zhou, Z., Xu, Y., & Li, J. (2026). PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy. Advanced Science, 13(61). https://doi.org/10.1002/advs.77089
Vancouver
Liu P, Chen Q, Zhou Z, Xu Y, Li J. PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy. Advanced Science. 2026;13(61). doi:10.1002/advs.77089
BibTeX
@article{Liu2026,
author = {Liu, Peng and Chen, Qiang and Zhou, Zhe and Xu, Yuekang and Li, Jinyao},
title = {PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {61},
doi = {10.1002/advs.77089}
}
EUVIMED